Objective: Rare coexistence of disease or pathology Background: Bladder cancer (BC) is the
second most common cancer involving the urinary system. In non-muscle-invading BC …

Abstract Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice
for superficial bladder carcinoma. We report a case of disseminated BCG infection in an …

Abstract Background Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the
treatment of choice for superficial bladder carcinoma. Complications of BCG therapy include …

DISCUSSION: BCG is derived from an attenuated strain of virulent Mycobacterium bovis that
can cause disease in humans. Hypersensitivity pneumonitis to BCG treatments has been …

Abstract Intravesical Bacillus Calmette-Guérin (BCG) instillation is a mainstay of adjunctive
therapy for superficial bladder cancer that increases length of disease progression-free …

Abstract Bacillus Calmette-Guérin (BCG) is the most effective intravesical immunotherapy for
superficial bladder cancer. Although generally well tolerated, BCG-related infectious …

Abstract Intravesical bacillus Calmette-Guérin (BCG) is used for urothelial carcinoma.
Systemic side effects are rare and commonly include organ involvement but rarely include …

Introduction Intravesical therapy with bacillus Calmette-Guérin (BCG) has proved to be
effective in the treatment of superficial bladder tumors. Side-effects include local infections …

Intravesical instillation of bacillus Calmette-Guérin (BCG) is the adjuvant therapy for
superficial urothelial carcinoma of the bladder with the lowest recurrence rates and is well …

Abstract Bacillus Calmette-Guerin (BCG) immunotherapy is a mainstay of adjunctive therapy
for non-muscle-invasive bladder cancer. The instillation of BCG in the upper urinary tract …